Ovarian Cancer Canada and the Quebec-Clinical Research Organization in Cancer (Q-CROC) are teaming up to work together to optimize the support available to women affected by ovarian cancer.
“Q-CROC is pleased to collaborate with Ovarian Cancer Canada, an organization that advocates for the health and wellbeing of women with ovarian cancer, and other at risk of this disease while advancing research to save lives. By working together, our two organizations will improve access to ovarian cancer clinical trials in Quebec.” – Lucie D’Amours, General Manager of Q-CROC
“Working collaboratively with partners is essential to make the greatest impact, serve those who need us most and reach more people experiencing ovarian cancer. We are proud to partner with Q-CROC to provide the ovarian cancer community in Quebec access to vital resources and information about clinical trials that have the potential to improve survival and quality of life,” says Tania Vrionis, CEO, Ovarian Cancer Canada.
Did you know?
About 3,000 Canadian women were diagnosed with ovarian cancer in 2022 and that every five hours someone dies from it in Canada. With a few exceptions, treatment options have not changed significantly since the 1990s and, unlike other types of cancer, the prognosis for ovarian cancer has not improved significantly in the past 50 years. Research initiatives and projects, including those funded by Ovarian Cancer Canada, are important for the development of new treatments.
In Quebec, about 30 clinical trials are currently open in Montreal, Laval, Quebec City and Sherbrooke. About 40 women affected by ovarian cancer took part in a clinical trial in 2022. Increased participation in clinical research is an important goal to support the development of tomorrow’s treatments and to provide a better understanding of the disease. To find out which clinical trials are recruiting participants in Quebec, visit www.oncoquebec.com